Business Context and Reporting Period
Company: Quantum Cyber N.V. (formerly Mainz Biomed N.V.)
Filing Type: Form 10-Q
Period Ended: June 30, 2026
Reporting Status: Smaller Reporting Company, Non-Accelerated Filer, Emerging Growth Company
The Company underwent a strategic pivot during the reporting period, exiting its colorectal cancer screening business (classified as discontinued operations) to focus on pancreatic cancer screening and a new venture in AI-enabled autonomous drone systems and post-quantum cybersecurity. The Company changed its name and ticker symbol (QUCY) in April 2026.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue (Continuing Ops) | $0 | $0 |
| Net Loss (Total) | $(16,098,462) | $(8,482,724) |
| Loss from Continuing Operations | $(12,557,915) | $(4,449,442) |
| Loss from Discontinued Operations | $(3,540,547) | $(4,033,282) |
| Operating Expenses (Continuing) | $12,351,976 | $4,375,600 |
| Cash and Cash Equivalents (End of Period) | $13,454,652 | $1,911,069 |
| Working Capital | $13,688,303 | $(471,824) |
| Total Assets | $23,367,895 | $5,327,396 |
| Total Liabilities | $3,004,556 | $4,685,796 |
| Accumulated Deficit | $(121,000,837) | $(104,902,375) |
Material Changes vs. Prior Period
- Strategic Pivot & Discontinued Operations: The Company divested its ColoAlert and NextGen colorectal cancer assets. Revenue from these discontinued operations was $184,670 for the six months ended June 30, 2026, compared to $286,717 in the prior year. The loss from discontinued operations improved slightly to $(3.54) million from $(4.03) million.
- Operating Expenses Surge: Operating expenses for continuing operations increased by 182% to $12.35 million. This was driven primarily by a $4.26 million charge for In-Process Research and Development (IPR&D) related to the acquisition of quantum antenna technology from Project LightShift and increased G&A expenses ($6.03 million vs $2.17 million) due to new management recruitment and stock-based compensation.
- Liquidity Improvement: Cash balances increased significantly from $889,091 at year-end 2025 to $13.45 million at June 30, 2026. This was fueled by $6.0 million in preferred stock proceeds and $15.2 million from warrant exercises.
- Asset Base Expansion: Total assets grew to $23.4 million, largely due to the acquisition of intangible assets (licenses) valued at $6.5 million and cash inflows.
Outlook, Risks, and Management Commentary
- Going Concern: Management has raised substantial doubt about the Company's ability to continue as a going concern due to recurring losses and an accumulated deficit of $121 million. The Company relies on future equity or debt financing to meet obligations for the next 12 months.
- New Business Strategy: The Company is launching an autonomous defense platform (Quantum Drones) and has entered into exclusive licenses with BP United and Project LightShift. A manufacturing plant acquisition (Arcade Technology) closed in July 2026.
- Internal Controls: The Company disclosed a material weakness in internal control over financial reporting. Deficiencies include a lack of written policies, inadequate documentation, and insufficient segregation of duties, leading to potential misstatements.
- Risk Factors: Key risks include the inability to successfully execute the strategic transition to drone/quantum technologies, dependency on third-party licenses, manufacturing integration challenges, and potential dilution from future capital raises.
- Subsequent Events: In August 2026, significant preferred shares were converted into ordinary shares, and the Company issued additional restricted shares for advisory services and license obligations.
Investor Verification Checklist
- Capital Sufficiency: Verify if the $13.4 million cash balance is sufficient to fund the new drone manufacturing ramp-up and R&D without immediate dilution, given the "substantial doubt" going concern warning.
- License Milestones: Confirm the status of performance conditions for the Project LightShift license (prototype delivery by Dec 31, 2026) and BP United license, as failure could result in forfeiture of shares or technology.
- Internal Control Remediation: Review the specific plan and timeline for remedying the material weakness in internal controls to ensure future financial reporting reliability.
- Discontinued Operations Settlement: Ensure all liabilities related to the German subsidiary wind-down and asset sales (ColoAlert/NextGen) are fully settled and no contingent liabilities remain.
- Dilution Impact: Assess the impact of the recent conversion of Series A, B, C, and D preferred shares (resulting in 55+ million new ordinary shares) on existing shareholder ownership.